Skip to main content

Advertisement

SpringerLink
Log in

Blood pressure as an example of a biomarker that functions as a surrogate

  • Published:
The AAPS Journal Aims and scope Submit manuscript

Abstract

There are many important uses of biomarkers in drug development. An area of particular interest is the use of biomarkers as surrogate end points. Only a small minority of biomarkers are established surrogate end points. Blood pressure is an example of a surrogate end point accepted by both clinicians and regulators. It was a plausible surrogate because of the large epidemiologic databases demonstrating a correlation between elevated blood pressures and adverse cardiovascular outcomes. That plausibility has been supported, however, by the numerous placebo-controlled outcome studies evaluating several pharmacologically distinct agents that showed an effect on stroke and coronary heart disease outcomes from lowering blood pressure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.Clin Pharmacol Ther. 2001;69:89–95. Quotation from page 91.

    Article  Google Scholar 

  2. Temple R. Are surrogate markers adequate to assess cardiovascular disease drugs?JAMA. 1999;282:790–795. Quotation from page 790.

    Article  CAS  PubMed  Google Scholar 

  3. Echt D, Liebson P, Mitchell L, et al. CAST Investigators. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial.N Engl J Med. 1991;324:781–788.

    Article  CAS  PubMed  Google Scholar 

  4. Packer M, Carver J, Rodehoffer R, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.N Engl J Med. 1991;325:1468–1475.

    Article  CAS  PubMed  Google Scholar 

  5. White PD.Heart Disease. New York, NY: MacMillan Company, 1931. Quotation from page 400.

    Google Scholar 

  6. Goldring W. Hypertension: seven decades of treatment.Bull NY Acad Med. 1969;45:902–909.

    CAS  Google Scholar 

  7. Fry J. Natural history of hypertension.Lancet. 1974;2:431–433.

    Article  CAS  PubMed  Google Scholar 

  8. Prentice R, Surrogate endpoints in clinical trials: definition and operational criteria.Stat Med. 1989;8:431–440.

    Article  CAS  PubMed  Google Scholar 

  9. Fleming TR, DeMets DL. Surrogate endpoints in clinical trials: are we being misled?Ann Intern Med. 1996;125:605–613. Quotation from page 605.

    Article  CAS  PubMed  Google Scholar 

  10. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias.Lancet. 1990;335:765–774.

    Article  CAS  PubMed  Google Scholar 

  11. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment.JAMA. 1996;275:1571–1576.

    Article  CAS  PubMed  Google Scholar 

  12. Neaton J, Wentworth D, Sherwin R, et al. Comparison of 10-year Coronary and Cerebrovascular Disease Mortality Rates by Hypertensive Status for Black and Non-Black Men Screened in the Multiple Risk Factor Intervention Trial (MRFIT) [abstract]Circulation 1989;80(4): Abstract 1195.

    Google Scholar 

  13. Davey Smith G, Neaton JD, Wentworth D, Stamler R, Stamler J. Mortality differences between black and white men in the USA: contribution of income and other risk factors among men screened for the MRFIT.Lancet. 1998;351:934–939.

    Article  CAS  PubMed  Google Scholar 

  14. Van Den Hoogen P, Feskens E, Nagelkerke N, et al. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world.N Engl J Med. 2000;342:1–8.

    Article  PubMed  Google Scholar 

  15. Neaton J, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease: overall findings and differences by age for 316,099 white men.Arch Intern Med. 1992;152:56–64.

    Article  CAS  PubMed  Google Scholar 

  16. Blaufox MD, Frishman WH, Miller G, et al. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP).JAMA. 1991;265:3255–3264.

    Article  Google Scholar 

  17. Staessen J, Fagard R, Thijs L, et al. Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension.Lancet. 1997;350:757–764.

    Article  CAS  PubMed  Google Scholar 

  18. VA Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressure averaging 115 through 129 mm Hg.JAMA. 1967;202:1028–1034.

    Article  Google Scholar 

  19. VA Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension, II: results in patients with diastolic blood pressure averaging 90 through 114 mm Hg.JAMA. 1970;213:1143–1152.

    Article  Google Scholar 

  20. Hypertension Detection and Follow-Up Program Cooperative Research Group. Five-year findings of the Hypertension Detection and Follow-up Program: reduction in mortality of persons with high blood pressure, including mild hypertension.JAMA. 1979;242. 2562–2571.

    Article  Google Scholar 

  21. Management Committee. The Australian Therapeutic Trial in Mild Hypertension.Lancet. 1980;1:1261–1267.

    Google Scholar 

  22. MRC Working Party. MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party.BMJ. 1985;291:97–104.

    Article  Google Scholar 

  23. Amery A, Birkenhager W, Brixko P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial.Lancet. 1985;1:1349–1354.

    Article  CAS  PubMed  Google Scholar 

  24. Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care.BMJ. 1986;293:1145–1151.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Dahlof B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension).Lancet. 1991;338:1281–1285.

    Article  CAS  PubMed  Google Scholar 

  26. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party.BMJ. 1992;304:405–412.

    Article  Google Scholar 

  27. UK Prospective Diabetes Study Group. Tight blood pressure and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38.BMJ. 1998;317:703–713.

    Article  PubMed Central  Google Scholar 

  28. HOPE Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.N Engl J Med. 2000;342:145–153.

    Article  Google Scholar 

  29. Dahlof B, Devereux R, Kjeldsen S, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension Study (LIFE): a randomised trial against atenolol.Lancet. 2002;359:995–1003.

    Article  CAS  PubMed  Google Scholar 

  30. Officers ALLHAT. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone.JAMA. 2000;283:1967–1975.

    Article  Google Scholar 

  31. Lewis E, Hunsicker L, Clarke W, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.N Engl J Med. 2001;345:851–860.

    Article  CAS  PubMed  Google Scholar 

  32. Officers ALLHAT. Major cardiovascular events in hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic.JAMA. 2002;288:2981–2997.

    Article  Google Scholar 

  33. Wing L, Reid C, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly.N Engl J Med. 2003;348:583–592.

    Article  CAS  PubMed  Google Scholar 

  34. Dahlof B, Sever P, Poulter N, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial.Lancet. 2005;366:895–906.

    Article  PubMed  Google Scholar 

  35. New Drug, Antibiotic, and Biological Drug Product Regulations, Accelerated Approval. Final rule. 57Federal Register 58942 (1992).

Download references

Author information

Authors and Affiliations

  1. Division of Cardiovascular and Renal Products (HFD-110, Food and Drug Administration, Bldg 22, 10903 New Hampshire Ave, 20993, Silver Spring, MD

    Mehul Desai, Norman Stockbridge & Robert Temple

Authors
  1. Mehul Desai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Norman Stockbridge
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert Temple
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mehul Desai.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Desai, M., Stockbridge, N. & Temple, R. Blood pressure as an example of a biomarker that functions as a surrogate. AAPS J 8, 17 (2006). https://doi.org/10.1208/aapsj080117

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1208/aapsj080117

Keywords

Search

Navigation